SOPH News & Events

Sophia Genetics files to sell 75,000 ordinary shares for holders

Sees FY26 revenue to represent approximately 20%-22% vs. last year. Sees FY26 adjusted EBITDA between ($29M)-($32M).

Reports Q4 revenue $21.7M vs. $17.7M last year. Performance in the quarter was driven by 45% year-over-year analysis growth in North America and 32% in Asia Pacific. "We finished 2025 strong, with Q4 revenue growing 22% and full-year revenue increasing 19% year-over-year, as our growth momentum continues to accelerate," said CEO Jurgi Camblong.

Sophia Genetics added two of the largest U.S. healthcare systems to its network. The two new institutions, which collectively analyze millions of genetic samples annually, include one of the leading nonprofit, multi-region integrated healthcare systems in the U.S. and a top 10 U.S. health system laboratory. Together, these institutions will leverage the AI-native, cloud-based SOPHiA DDM to analyze complex genomic data at scale. By adopting SOPHiA DDM, the two institutions will initially launch genomic testing for up to 60,000 patients annually across the West Coast and Midwest. Both health systems will utilize SOPHiA DDM for Enhanced Exome, an AI-driven analytics application that supports comprehensive full-exome analysis for over 20,000 genes while enabling the ability to dive deeper into clinically relevant regions. The institutions aim to expedite testing turnaround times, streamline operational costs, and expand internal research and innovation initiatives.